Zenith Capital Corp. (ZHCLF)

OTCMKTS · Delayed Price · Currency is USD
0.1000
+0.0500 (100.00%)
Jan 22, 2026, 4:00 PM EST
99,900%
Market Cap15.97M
Revenue (ttm)500.00K
Net Income (ttm)-6.82M
Shares Out159.73M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,000
Average Volume11,745
Open0.1000
Previous Close0.0500
Day's Range0.1000 - 0.1000
52-Week Range0.0001 - 0.1400
Beta670.41
RSI53.23
Earnings DateApr 6, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer I... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol ZHCLF
Full Company Profile

Financial Performance

Financial Statements